@rheumnow #acr20 #absL03 RCDB PC ph2 trial TYK2i Deucravacitinib for PsA: ACR 20 at 16wk 6 mg 52.9% & 12 mg 62.7% vs PBO 31.8%. csDMARD & TNFi failure included. no serious infections, herpes zoster, opportunistic infections, or thrombotic events https://t.co/WVm4llPv5i

No need to stop Tofa w/the flu? 👉Posthoc analysis 7964 Tofa pts over 14-15 flu seasons reported similar flu rates compared to ADA, MTX, PCB. 👉Tofa cont. in 70% pts; 28.8% stopped; mean days to resolution similar. Abstr#L04 #ACR20 @rheumnow #ACRBest https://t.co/rZXKRVl7uK

• Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitin…

#Curcumin for PsA & RA?🤔 Results suggest curcumin's efficacy on pt's perceived symptom alleviation & poss correlation w/ dose and length of tx. @RheumNow #ACR20 abs1230 https://t.co/xUxUEW02ww

Lots of interesting studies in Spondyloarthritis including AxSpA and PsA at #ACR20 @RheumNow https://t.co/tIyqyMdmTf

• https://twitter.com/rheumnow/status/1325475676640645128

PsA still has ^mortality vs general marched pop’n. Can we do better for our pts? Abstr#1476 @RheumNow @CRASCRRheum #ACR20 https://t.co/aDkTF9dFF0

• https://twitter.com/lihi_eder/status/1325574894604660737

When do you tend to change tx strategies in PsA? #ACR20 @RheumNow

Despite 30% decrease in mortality over the past 2 decades, the mortality gap remains in psoriasis and #PsA. #ACR20 Abstract #1476 by @Keith_Colaco. @NPF @WCRInstitute @researchuoft @RheumNow @rheum_cat https://t.co/CXTELMJh8P

#Multimorbidity in #RheumaticDisease: Abs#1466: -Highly prevalent across RA, PsA, gout & OA -Highest burden in #gout Important study highlighting need to recognise burden of MM in #rheumatology patients for holistic optimised management. #ACR20 @RheumNow https://t.co/esinnHoUME https://t.co/bApXfx7hOU

• Multimorbidity in Rheumatoid Arthritis, Psoriatic Arthritis, Gout, and Osteoart…